CJC-1295 + Ipamorelin | Benefits, Safety & Buying Advice ...

Photo by Innerbody Research

In addition to their uses in areas like weight loss, immune modulation, and cognitive enhancement, therapeutic peptides have demonstrated high potential to improve physical performance and body composition. Weight lifters, bodybuilders, and other gymgoers have taken to using them for these reasons. And for many, a combination of CJC-1295 and ipamorelin is the best treatment for both enhancing and accelerating their gains.

In this guide, we discuss how CJC-1295 and ipamorelin work synergistically to help you increase your lean mass while decreasing your body fat. We also cover their other therapeutic uses, their significant safety risks, and other factors you’ll want to consider before starting treatment, including where to get a pharmaceutical-grade version of the combination.

On that last point, if you’ve already decided you want to explore treatment, we currently recommend a concierge telehealth peptide clinic called Protocole, which includes the CJC-1295 and ipamorelin stack in its extensive and growing catalog.

Our Top Pick

Protocole’s variety of pharmaceutical-grade treatments and comprehensive concierge service distinguish it in the field of peptide telehealth.

Its CJC-1295 and ipamorelin stack is competitively priced at $325 for a five-week supply, and you can even get it in an advanced stack that includes the muscle-growth peptide BPC-157. As Protocole’s catalog continues to grow, you may see additional treatment options down the line. In the meantime, its team of licensed clinicians can develop for you a curated regimen tailored to your present health goals and needs.

Jump to

Jump to:

Why should you trust us?

Over the past two decades, Innerbody Research has helped tens of millions of readers make more informed decisions about staying healthy and living healthier lifestyles.

We’ve been following the therapeutic peptide space for years. So far, we’ve cumulatively studied several hundred pieces of scientific literature across more than 500 hours. No doubt, by the time you read this, these numbers will have increased exponentially. And aside from what we’ve read in peer-reviewed journals, we’ve also consulted with clinicians who prescribe peptides, spoken with peptide users, and even used peptides ourselves. Our knowledge is both theoretical and practical, and it’s always growing.

Additionally, like all health-related content on this website, this guide was thoroughly vetted by one or more members of our Medical Review Board for accuracy and will continue to be monitored for updates by our editorial team.

What are CJC-1295 and ipamorelin?

CJC-1295 and ipamorelin belong to a category of synthetic therapeutic peptides called growth hormone secretagogues, or substances that promote the secretion of growth hormone. Growth hormone, for its part, increases cellular replication, encourages collagen synthesis in your skeletal muscles, and stimulates the production of a separate hormone called insulin-like growth factor-1 (IGF-1), which helps regulate the process by which your body creates fat.1 2 3 Given these qualities, a higher concentration of circulating growth hormone can lead to improved exercise training, increased muscle strength, and a decreased propensity for fat accumulation.4

Despite belonging to the same category and effecting a common outcome, CJC-1295 and ipamorelin have distinct mechanisms of action:

CJC-1295’s mechanism of action

CJC-1295 mimics a chemical from the hypothalamus called growth hormone-releasing hormone (GHRH), which tells the pituitary gland to release growth hormone.5

Ipamorelin’s mechanism of action

Ipamorelin is an analog of ghrelin, a hormone originating from the cells in your stomach.6 As such, it binds to the brain’s ghrelin receptor and, like GHRH, stimulates growth hormone secretion from the pituitary. Importantly, its secretagogue action is selective, having no effect on stress hormones like cortisol, an overpresence of which can cancel your efforts to gain muscle or shed fat.7 8

Why are CJC-1295 and ipamorelin used together?

CJC-1295 and ipamorelin are commonly used together because they have complementary time-release characteristics:

• CJC-1295 is effectively GHRH that has been modified to have a longer half-life, so it stimulates pituitary growth hormone secretion in a sustained manner over an extended period.9
• Ipamorelin acts on the pituitary gland directly, inducing a more immediate dump of growth hormone into circulation.

Hence, using the two peptides in combination allows you to take advantage of growth hormone in terms of both availability and intensity — the tortoise and the hare as relay partners.

INNERBODY NEWSLETTER

Ready for the ultimate sleep upgrade?

Your privacy is important to us

Current therapeutic uses for CJC-1295 and ipamorelin

Like sermorelin, another growth hormone secretagogue, CJC-1295 and ipamorelin are non-FDA-approved medications whose therapeutic uses are entirely off-label. Nonetheless, scientific research suggests that their combined growth hormone secretagogue actions may be particularly effective at achieving the following health outcomes:

Increasing growth hormone circulation

Though not exactly common, growth hormone deficiency affects enough people (1 in every 10,000 adults) and causes serious enough problems (depression, insulin resistance, increased body fat) that it behooves us to have a reliable treatment for it.10

To that end, several studies have vouched for CJC-1295 and ipamorelin, at least as separate therapies. For example:

• Two human trials — one in 2006, the other in 2013 — found that even very small weekly doses (30-90mcg) of CJC-1295 resulted in “increased [minimum] and mean [growth hormone] secretion and ... pulsatility” as well as “sustained, dose-dependent increases in [growth hormone] and IGF-I levels in healthy adults.”11 9
• In 1999, a human trial with 40 total volunteers concluded that ipamorelin at multiple doses induces growth hormone secretion at sufficient levels to be biologically effective, with peak concentration arriving within an hour.12

These studies examined the two peptides separately, but their results validate the mechanisms of action that underlie the reason that CJC-1295 and ipamorelin are used together. That is, both effectively stimulate growth hormone secretion, and each one does so at a complementary rate of time release — one sustained, the other immediate.

Muscle gain and fat loss

Direct assessments of CJC or ipamorelin on body composition are scarce, but numerous studies have linked increased growth hormone circulation to muscle gain and fat loss.13

By way of example, you might consider a 2013 trial that led to improved muscle strength after six months of growth hormone therapy in men over 50 years old, an age group likely to notice the effects of age-related muscle loss.4 14 You might also look at a 2014 paper published in the Journal of Molecular Endocrinology, which concluded that growth hormone “exerts complex multi-system effects on skeletal muscle function” ultimately to increase muscle mass.15 If not that, then perhaps a 1999 study that saw growth hormone recipients lose more weight and gain more lean body mass than their placebo-group counterparts.16

Other benefits of CJC-1295 and ipamorelin

Along with their combined effects on growth hormone, muscle, and fat, CJC-1295 and ipamorelin may provide additional health benefits with varying degrees of scientific support:

Injury recovery

Remember, part of what makes growth hormone effective for muscle growth is that it increases cellular replication.1 Coincidentally, cellular replication plays a key part in a complex biochemical process that allows you to heal from an injury.17

The research is mixed as to the use of growth hormone secretagogues to facilitate injury recovery. On the one hand, a 2020 pilot study showed that increased growth hormone circulation could preserve quadriceps strength in patients who’d undergone reconstructive surgery after an anterior cruciate ligament injury;18 on the other, an in vitro study from 2024 found that growth hormone administered to tendon and ligament cells “[did] not appear to positively affect cellular proliferation and differentiation.”19

More research is needed before we can say for sure whether CJC-1295, ipamorelin, and similar peptide treatments have dependable utility toward injury recovery.

Sleep quality

Studies since at least the 1990s have shown that higher GHRH activity can decrease wakefulness and increase slow-wave sleep.20 21 The relationship has to do with GHRH being necessary to slide you into the deepest sleep stages and keep you there.22 So the science supports using something like CJC-1295 to get more shut-eye.

By the way, CJC’s sleep-promoting potential works in favor of your muscle-building pursuit, as sufficient rest is a requisite for skeletal muscle protein synthesis.23

Antiaging and longevity

While it’s true that growth hormone levels naturally decline with age, likely contributing to age-related physiological changes, there’s no good evidence to suggest that increasing growth hormone via GHRH or ghrelin can slow those changes.24 13

Are CJC-1295 and ipamorelin safe to use?

Owing to the following health risks, CJC-1295 and ipamorelin are moderately unsafe for the general population compared to some of the other peptides we’ve studied:

• Immunogenicity: Immunogenicity is a condition in which your body interprets a substance as a threat and mounts an immune response against it. The FDA warns that both CJC-1295 and ipamorelin are risky for immunogenicity, potentially causing life-threatening outcomes such as anaphylaxis.25 26
• Cardiovascular concerns: Specifically concerning CJC-1295, the FDA warns of the risk of “increased heart rate and systemic vasodilatory reaction,” including “flushing, warmth, and transient hypotension.”25 27
• Cancer: With their ability to increase the rate of cellular replication, growth hormone secretagogues in general are unsafe for cancer survivors and people with an active cancer diagnosis.28 Secretagogue use may elevate their risk for recurrence or worsen their prognosis.

With ipamorelin, there’s also a risk of death when it’s injected intravenously.25 It’s important here to note that peptides like ipamorelin are normally injected under the skin, not into a vein, and your prescribing physician is very unlikely to recommend the intravenous route.

In addition, CJC-1295 and ipamorelin carry the same risk of milder side effects associated with many injectable peptides, namely injection site reactions and mild flu-like symptoms.

Research-grade vs. pharmaceutical-grade CJC-1295 and ipamorelin

Many of the therapeutic peptides you can purchase online are research-grade products, and that’s certainly the case with CJC-1295 and ipamorelin. “Research-grade” means that the peptides are designed exclusively for testing purposes, in laboratories. They are not intended for human consumption, as they lack the same purity and quality controls as their medical-grade counterparts. The best way to manage safety concerns associated with CJC-1295 and ipamorelin is to access them after assessment by a medical professional, but even aside from those safety concerns, you certainly don’t want to contend with the risk of infection or genotoxicity posed by research-grade products.29

Therefore, to get CJC-1295 and ipamorelin that are fit for human use, you must go through a licensed clinician who will write you a prescription to be filled at an accredited compounding pharmacy.

What’s it like to use CJC-1295 and ipamorelin?

Treatment protocols can vary depending on the prescriber and the patient, but there are usually some commonalities despite the variables. So, notwithstanding potential differences, here’s what you might expect with your CJC-1295 and ipamorelin therapy:

Preliminary and ongoing lab tests

Your physician may order lab tests to assess your candidacy for CJC-1295 and ipamorelin. These tests help to determine the proper dosage as well as reveal biomarkers to rule out health problems and other contraindications.

As your treatment is underway, your physician may also periodically order additional lab tests to determine how your body is responding to the peptides. Depending on the test results, they might adjust your dosage and protocol.

Dosing and administration

Injectable therapeutic peptides normally come in a vial containing a month’s worth of medicine, requiring you to measure each injection according to your prescriber’s instructions. In the case of CJC-1295 and ipamorelin, both medicines are compounded into the same vial.

Though dosages may vary based on variables like age and weight, a typical starting dose of CJC-1295 and ipamorelin is 0.2mg per injection. The injection should go into an area of subcutaneous fat, such as your belly, a thigh, or an arm.

A month’s supply of treatment will probably include at least:

• A vial of peptide powder
• A vial of bacteriostatic water
• Needle syringes
• Alcohol swabs

Before using the treatment, you must reconstitute the powder with the bacteriostatic water to create an injectable solution. On that matter, you should carefully follow your prescribing physician’s instructions.

Treatment protocol

Your CJC-1295 and ipamorelin treatment protocol might look like this:

• Five doses per week
• Nighttime administration (ideally a couple of hours after your last meal, to align with your body’s natural growth hormone release)21
• Periodic biomarker retesting

Clinicians often recommend cycling the use of therapeutic peptides to prevent desensitization and maintain therapeutic efficacy. Cycling just means taking the treatment regularly for a specific period before taking a break from it. A typical CJC-1295 and ipamorelin cycle is four months — three months on, one month off — so you’d complete three cycles per year.

As you proceed with your treatment protocol, you should notice health effects incrementally. Though the exact onset of these effects will vary depending on your age and physicality, you can expect them to follow this timeline:

• Within 4-6 weeks, with regular resistance training, you ought to notice a more defined muscular contour, speedier recovery between workout sessions, and perhaps some reduced body fat.
• In 8-12 weeks, the above changes become more apparent. You might also notice cosmetic improvements in skin quality.

Thereafter, it’s about sustaining your health improvements with ongoing compliance with your treatment protocol.

As with many therapeutic peptides, you need to continue using CJC-1295 and ipamorelin to continue seeing results.

Storage

Reconstituted therapeutic peptides must be stored properly to prevent rapid degradation. The U.K.’s National Institute for Biological Standards and Control (NIBSC) recommends storage in a “dry, cool, dark place” at around 4°C (approximately 39°F).30 Your refrigerator, then, is the ideal storage container. There, your supply of CJC-1295 and ipamorelin ought to remain stable for several weeks.

Who’s a candidate for CJC-1295 and ipamorelin?

With their elevating effect on growth hormone levels and attendant impacts on body composition, CJC-1295 and ipamorelin are best suited for anyone without a contraindicating health condition who wants to increase their lean muscle mass and shed fat. That’s a user population that includes not only weight lifters and bodybuilders but also people at risk for:

Sarcopenia

The worldwide prevalence of sarcopenia, or age-related muscle loss, is 10-16%, so it’s far from uncommon.31 And because people begin to lose 3-8% of their existing muscle mass with every proceeding decade of adult life, it behooves you to take active measures to preserve the lean mass you have.32 Otherwise, you may find yourself struggling with physical weakness and decreased physiological function as you grow older.33 Resistance training can mitigate the risk, and a growth hormone secretagogue peptide can support your resistance training.

Adult growth hormone deficiency

Adult growth hormone deficiency is rare, but its impact can be serious. Arising from causes such as traumatic brain injury and pituitary or hypothalamic tumors, it can negatively affect your strength, stamina, mood, sexual function, and much more.34 35 Increasing your growth hormone levels is the standard treatment.

Who’s not a candidate for CJC-1295 and ipamorelin?

Besides people in whom CJC-1295 and ipamorelin may pose an elevated health risk, the treatments are broadly contraindicated in:

• People who are pregnant or breastfeeding, as there isn’t enough evidence to determine their general safety for the developing fetus or newborn
• People who fear needles, as subcutaneous injection is the most common route of administration
• Competitive weight lifters or bodybuilders — less for safety reasons than because these peptides are prohibited by the World Anti-Doping Agency

Where to find CJC-1295 and ipamorelin

The only way to get medical-grade CJC-1295 and ipamorelin is from an accredited compounding pharmacy, after visiting with a licensed clinician. Availability may be scarce, as the categorical status of CJC-1295 and ipamorelin is in limbo. At this writing, the FDA has yet to determine whether these peptides will be included on the 503A bulks list, the agency’s roster of substances allowed to be used in drug compounding. They currently hold “category 2” status on this list, which makes it far more difficult for pharmacies to compound them legally, although legal challenges have suspended any enforcement against compounding these (and other) peptides.36

That’s not to say that you can’t get them legally. In fact, you can access pharmaceutical-grade versions through various peptide clinics, whether brick-and-mortar or online.

For the online route, remember that numerous websites will sell you research-grade versions of CJC-1295 and ipamorelin, but research-grade peptides are definitively unsafe for human consumption. Instead, you want to deal with a reputable telehealth company that offers pharmaceutical-grade peptides and access to licensed prescribing physicians.

That kind of opportunity right now is fairly scarce, but there’s at least one provider we recommend at this time. It’s called Protocole, a concierge telemed service with a wide variety of peptide treatments. There, you can access CJC-1295 and ipamorelin as an individual stack ($325), an advanced stack ($550), or part of a well-devised cocktail of treatments curated by Protocole’s clinicians. Your options may increase in the future as Protocole continues to develop its lineup. Get approved for a membership and explore the catalog to see your options in-depth.

Photo by Innerbody Research

Innerbody uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.

1. Brinkman, J. E., et al. (2023). Physiology, growth hormone. StatPearls [Internet].

2. Doessing, S., et al. (2009). Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis. The Journal of Physiology, 588(pt. 2), 341-351.

3. Rong, P., et al. (2025). Targeting IGF1 to alleviate obesity through regulating energy expenditure and fat deposition. Science China Life Sciences.

4. Tavares, A. B. W., et al. (2013). Effects of growth hormone administration on muscle strength in men over 50 years old. International Journal of Endocrinology, 2013, 942030.

5. Utiger, R. D. (n.d.). Growth hormone-releasing hormone. Britannica.

6. Cleveland Clinic. (2022). Ghrelin. Cleveland Clinic.

7. National Cancer Institute. (n.d.). Ipamorelin. National Institutes of Health.

8. Thau, L., Gandhi, J., & Sharma, S. (2023). Physiology, cortisol. StatPearls [Internet].

9. Teichman, S. L., et al. (2005). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology and Metabolism, 91(3), 799-805.

10. Cleveland Clinic. (2022). Growth hormone deficiency (GHD). Cleveland Clinic.

11. Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting gh-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797.

12. Gobburu, J. V. S., et al. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16, 1412-1416.

13. Mayo Clinic Staff. (2024). Human growth hormone (HGH): Does it slow aging? Mayo Clinic.

14. Harvard Medical School. (2016). Preserve your muscle mass. Harvard Health Publishing.

15. Chikani, V., & Ho, K. K. Y. (2014). Action of GH on skeletal muscle function: Molecular and metabolic mechanisms. Journal of Molecular Endocrinology, 52(1), R107-R123.

16. Kim, K. R., et al. (1999). Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults. Hormone Research, 51(2), 78-84.

17. Vibert, L., Daulny, A., & Jarriault, S. (2018). Wound healing, cellular regeneration and plasticity: The elegans way. The International Journal of Developmental Biology, 62(6-7-8), 491-505.

18. Mendias, C. L., et al. (2020). The use of recombinant human growth hormone to protect against muscle weakness in patients undergoing anterior cruciate ligament reconstruction: A pilot, randomized placebo-controlled trial. The American Journal of Sports Medicine, 48(8), 1916-1928.

19. Baumgarten, K. M., Sandhurst, E. S., & Sun, H. (2025). Can human growth hormone accelerate tendon and ligament injury recovery? Sports Health, 17(2), 299-304.

20. Van Cauter, E., & Plat, L. (1996). Physiology of growth hormone secretion during sleep. The Journal of Pediatrics, 128(5, pt. 2), S32-37.

21. Zaffanello, M., et al. (2024). Complex relationship between growth hormone and sleep in children: Insights, discrepancies, and implications. Frontiers in Endocrinology, 14, 1332114.

22. Morselli, L. L., et al. (2013). Impact of growth hormone replacement therapy on sleep in adult patients with growth hormone deficiency of pituitary origin. European Journal of Endocrinology/European Federation of Endocrine Societies, 168(5), 10.1530/EJE-12-1037.

23. Morrison, M., et al. (2022). Sleep, circadian biology and skeletal muscle interactions: Implications for metabolic health. Sleep Medicine Reviews, 66, 101700.

24. Bartke, A. (2008). Growth hormone and aging: A challenging controversy. Clinical Interventions in Aging, 3(4), 659-665.

25. U.S. Food & Drug Administration. (2024). Certain bulk drug substances for use in compounding that may present significant safety risks. FDA.

26. U.S. Food & Drug Administration. (2014). Guidance for industry: Immunogenicity assessment for therapeutic protein products. FDA.

27. U.S. Food & Drug Administration. (2024). CJC-1295-related bulk drug substances (CJC-1295 [free base], CJC-1295 acetate, CJC1295 with drug affinity complex [DAC] [free base], CJC-1295 DAC acetate, and CJC-1295 DAC trifluoroacetate [TFA]). FDA.

28. Chae, W., Kim, H., & Kim, S. (2015). Growth hormone treatment and risk of malignancy. Korean Journal of Pediatrics, 58(2), 41-46.

29. Liu, F. (2024). Safety assessment of drug impurities for patient safety: A comprehensive review. Regulatory Toxicology and Pharmacology, 153, 105715.

30. National Institute for Biological Standards and Control. (n.d.). Peptide handling, dissolution & Storage. NIBSC.

31. Yuan, S., & Larsson, S. C. (2023). Epidemiology of sarcopenia: Prevalence, risk factors, and consequences. Metabolism — Clinical and Experimental, 144, 155533.

32. Volpi, E., Nazemi, R., & Fujita, S. (2004). Muscle tissue changes with aging. Current Opinion in Clinical Nutrition and Metabolic Care, 7(4), 405-410.

33. Cleveland Clinic. (2022). Sarcopenia. Cleveland Clinic.

34. Hoffman, A. R., et al. (2022). Adult growth hormone deficiency: Diagnostic and treatment journeys from the patients’ perspective. Journal of the Endocrine Society, 6(7), bvac077.

35. Cedars-Sinai. (n.d.). Adult growth hormone deficiency. Cedars-Sinai.

36. Safe Harbor Group. (2025, November 18). FDA’s Overreach on Compounded Peptides: How Clinics Can Push Back. safehg.com.